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Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has collapsed health systems
worldwide. In adults, the virus causes severe acute respiratory distress syndrome (ARDS), while in children the
disease seems to be milder, although a severe multisystem inflammatory syndrome (MIS-C) has been described.
The aim was to describe and compare the characteristics of the severe COVID-19 disease in adults and children.
Methods: This prospective observational cohort study included the young adults and children infected with SARS-
CoV-2 between March–June 2020 and admitted to the paediatric intensive care unit. The two populations were
analysed and compared focusing on their clinical and analytical characteristics and outcomes.
Results: Twenty patients were included. There were 16 adults (80%) and 4 children (20%). No mortality was
recorded.
All the adults were admitted due to ARDS. The median age was 32 years (IQR 23.3–41.5) and the most relevant
previous pathology was obesity (n = 7, 43.7%). Thirteen (81.3%) needed mechanical ventilation, with a median PEEP
of 13 (IQR 10.5–14.5). Six (37.5%) needed inotropic support due to the sedation. Eight (50%) developed a
healthcare-associated infection, the most frequent of which was central line-associated bloodstream infection (n = 7,
71.4%). One patient developed a partial pulmonary thromboembolism, despite him being treated with heparin.
All the children were admitted due to MIS-C. Two (50%) required mechanical ventilation. All needed inotropic
support, with a median vasoactive-inotropic score of 27.5 (IQR 17.5–30).
The difference in the inotropic requirements between the two populations was statistically significant (37.5% vs.
100%, p < 0.001). The biomarker values were higher in children than in adults: mid-regional pro-adrenomedullin 1.72
vs. 0.78 nmol/L (p = 0.017), procalcitonin 5.7 vs. 0.19 ng/mL (p = 0.023), and C-reactive protein 328.2 vs. 146.9 mg/L
(p = 0.005). N-terminal pro-B-type natriuretic peptide and troponins were higher in children than in adults (p = 0.034
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and p = 0.039, respectively).
Conclusions: Adults and children had different clinical manifestations. Adults developed severe ARDS requiring
increased respiratory support, whereas children presented MIS-C with greater inotropic requirements. Biomarkers
could be helpful in identifying susceptible patients, since they might change depending on the clinical features.
Keywords: SARS-CoV-2, COVID-19, Acute respiratory distress syndrome, Multisystem inflammatory syndrome,
Biomarkers
Background
The novel severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2), which first appeared in December
2019 in Wuhan, has caused the coronavirus (COVID-19)
related pandemic and has been declared a significant
threat to international health by the World Health
Organization. As of 20 December 2020, 75 million cases
have been reported across the globe, causing more than
1,6 million deaths [1]. It has collapsed health systems
worldwide, mainly due to its respiratory manifestations
in the adult population, causing many cases of acute
respiratory distress syndrome (ARDS) [2].
Interestingly, not all patients have the same mani-
festations; while some of them have hypoxemia due
to pneumonia with a ventilation/perfusion mismatch
(pulmonary vasoconstriction), others have this due to
lower compliance and severe ARDS [3]. By contrast,
in children the disease seems to be milder, with clin-
ical symptoms similar to other acute viral respiratory
infections, with a low mortality rate of around 0–0.2%
[4, 5]. There are many hypothesis regarding why chil-
dren are less affected by the disease. One possibility
is that the lower number of angiotensin-converting
enzyme 2 (ACE2) receptors in children’s nasal epithe-
lium limits virus entry, and the higher numbers of
ACE2 receptors in their lungs could act as a protect-
ive factor [6]. Recently, some reports have described
paediatric patients with a multisystem inflammatory
syndrome (MIS-C) that shares similarities with Kawa-
saki disease and toxic shock syndrome and can poten-
tially lead to multiorgan failure and shock [7].
Biomarkers related to the cytokine storm, since they
seem to have a role in detecting severely affected pa-
tients in other pathologies like sepsis [8], might be
useful to distinguish between the two clearly different
clinical manifestations.
Both ARDS and MIS-C are most likely post-infectious
manifestations. Little is known about the specific
immunity response after a SARS-CoV-2 infection. It
seems that there is an initial peak viral load (at which
point nasopharyngeal PCR samples can test positive for
the viral RNA), and then this declines as antibodies (IgM
and IgG) increase within days to weeks of symptom
onset, just when inflammatory signs appear [9].
However, both the durability of the neutralising anti-
bodies and whether there is persistent immunity against
reinfection is unclear [10].
Since the clinical presentation of the severe forms of
the disease implies a cytokine release syndrome with an
increase in interleukin-6 (IL-6), tocilizumab has been
pointed to as a useful treatment to decrease the inflam-
matory response [11]. In children there is no evidence
regarding specific treatments, since most studies involve
the adult population [4].
During the COVID-19 pandemic, both adult and
paediatric patients were admitted to our paediatric
intensive care unit (ICU), and a different clinical presen-
tation and evolution were detected in each group. The
aim of this study was to describe the characteristics of
the disease in each specific population and to analyse
the differences between adults and children regarding
the clinical manifestations and analytical data.
Methods
This was a prospective and observational cohort study,
performed in the paediatric ICU of Hospital Sant Joan
de Déu in Barcelona, which is a paediatric tertiary refer-
ral hospital. This paediatric ICU has 28 ventilator-beds
and sees 1200 admissions per year. All the patients
infected with SARS-CoV-2 (with a positive PCR result
from a nasopharyngeal swab and/or positive IgM or
IgG) admitted to the paediatric ICU between March and
June 2020 were included, both adults and children.
These two populations were analysed separately in order
to compare their clinical characteristics and outcomes.
Variables
The following demographic data were collected: age,
gender, comorbidities, Paediatric Risk of Mortality Score
(PRISM III) at admission (11), and reason for admission
(respiratory or cardiovascular failure). Respiratory sup-
port was also analysed: positive end-expiratory pressure
(PEEP), ventilator and oxygenation requirements (prone
position, recruitment manoeuvres), and length of mech-
anical ventilation (MV) and non-invasive ventilation
(NIV). Haemodynamic support requirements were ana-
lysed using the vasoactive inotropic score (VIS) (11) and
the length of the inotropic treatment. The need for
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heparin treatment was analysed: a high heparin dose was
considered as 1 mg/kg/12 h and a low heparin dose was
considered as 0.5 mg/kg/12 h. The microbiological data
collected included microorganisms isolated in the blood,
respiratory tract, and urine cultures. Antibiotic require-
ments and lengths of treatment were recorded. The ana-
lytical biomarkers recorded were C-reactive protein,
procalcitonin, mid-regional pro-adrenomedullin (MR-
proADM), ferritin, D-dimer, lactate dehydrogenase, and
blood counts. N-terminal pro-B-type natriuretic peptide
(NT-proBNP) and troponins were analysed in order to
assess cardiac dysfunction.
Serum levels of procalcitonin and MR-proADM were
determined by immunofluorescense by means of a
Time-Resolved Amplified Cryptate Emission (TRACE)
and a Kryptor analyser (B·R·A·H·M·S-Diagnostica
GmbH, Henningsdorf, Germany). C-reactive protein was
obtained using the immunoturbidimetric assay (COBAS
INTEGRA ROCHE).
The length of stay in the hospital and in the paediatric
ICU, as well as the mortality rate, were also recorded.
The patients were classified, depending on their clin-
ical presentation, as having:
– ARDS, identified following the Berlin Definition,
specifically, respiratory failure with bilateral
pulmonary opacities with PaO2 < 300 mmHg and
PEEP or CPAP > 5 cmH2O [12].
– MIS-C in children and adolescents, identified
according to the preliminary definition provided by
the World Health Organization, which specifies the
presence of shock, with elevated biomarkers and a
positive COVID-19 test, without other microbial
causes of inflammation [7]. These patients also met
the CDC criteria for MIS-C: an individual aged
under 21 years with fever, laboratory evidence of in-
flammation, and evidence of clinically severe illness
requiring hospitalisation, with multisystem organ in-
volvement AND no alternative plausible diagnosis
AND positive for current or recent SARS-CoV-2 in-
fection [13].
Statistical analysis
A statistical analysis was performed using the IBM SPSS
25.0 Statistics® programme. Categorical variables were
indicated as frequency (n) and percentage (%), whereas
continuous variables were summarised as median and
interquartile range (IQR) because they did not follow a
normal distribution, according to the Shapiro-Wilk test.
The comparison of categorical variables was performed
using the χ2-test or Fisher’s exact test. Continuous vari-
ables were compared using the Mann-Whitney U test.
Probability values of less than 0.05 were considered sta-
tistically significant.
Results
During the study, 20 patients were included. There were
16 adults (80%) and 4 children (20%). All the patients
had a positive PCR result from the nasopharyngeal sam-
ple except one child, who had suggestive clinical features
and a positive IgG. No patient needed extracorporeal
membrane oxygenation support and no deaths were
recorded.
Description of the adult patients
The 16 adults all presented with ARDS. The median age
was 32 years (IQR 23.3–41.5), and 11 (68.8%) had a rele-
vant previous pathology, the most frequent of which was
obesity (n = 7, 43.7%). Among them, 13 (81.3%) needed
MV, with a median maximum PEEP of 13 (IQR 10.5–
14.5). Prone position was required in 10 patients (76.9%)
and recruitment manoeuvres in 5 patients (38.5%). Six
patients (37.5%) required inotropic support, in all cases
due to sedation. All the patients received treatment with
heparin and 6 of them (37.5%) were on high doses. The
specific treatment related to COVID-19 is detailed in
Table 1.
Eight patients (50%) developed a healthcare-associated
infection, and the most frequent of them were central
line-associated bloodstream infections (n = 7, 43.8%) The
microbiological details are summarised in Table 2.
On the blood test, the patients presented low lympho-
cyte count, high triglycerides levels, and a high D-dimer
values during the clinical evolution. The median levels
for IL-6 were high. The median for MR-proADM was
0.78 nmol/L (IQR 0.64–0.88), for procalcitonin it was
0.19 ng/mL (IQR 0.11–0.37), and for C-reactive protein
it was 146.95 mg/L (IQR 57.6–193). The detailed results
of the blood sample tests are included in Table 2.
The adult patients had a median length of stay in the
ICU of 12 days (IQR 5.7–17), and they had a total length
of stay in the hospital of 21 days (IQR 13.7–29.8).
Description of the paediatric patients
Four children were admitted during the study period.
None of them had a pre-existing disease or risk fac-
tor. All presented with MIS-C and required admis-
sion to the paediatric ICU due to shock. Two of
them (50%) required MV, with low ventilator param-
eters, and two (50%) required NIV. All the patients
needed inotropic support due to the shock, with a
median VIS of 27.5 (IQR 17.5–30) and a median
length of inotropic treatment of 3 days (IQR 2–4.7).
Detailed information on the respiratory and haemo-
dynamic support is provided in Table 1.
On the blood test, the median lymphocyte count was
low, as well as the prothrombin time. IL-6 was high at
admission. The median for MR-proADM was 1.72 nmol/
L (IQR 1.55–2.77), for procalcitonin, 5.7 ng/mL (IQR
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Males, n (%) 11 (55) 9 (56.3) 2 (50) 1.000
Age (years) 29.5 (20.3–40) 32 (23.3–41.5) 13.5 (5.5–16.5) < 0.001
Risk factors 11 (55) 11 (68.8) 0 (0) 0.026
Obesity 7 (35) 7 (43.8)
Asthma 5 (25) 5 (31.3)
Arterial hypertension 2 (10) 2 (12.5)
Diabetes 1 (5) 1 (6.3)
Days of symptoms until admission 9.5 (7–11.8) 10.5 (8–12) 4 (2.3–6.5) 0.002
Reason for admission, n (%) < 0.001
Respiratory problems 16 (80) 16 (100) 0 (0)
Haemodynamic problems 4 (20) 0 (0) 4 (100)
PRISM III 6 (2.8–10) 6 (2.8–9.5) 8.5 (1.3–15.8) 0.567
Respiratory support
Mechanical ventilation, n (%) 15 (75) 13 (81.3) 2 (50) 0.249
- Maximum PEEP (cmH2O) 12 (10–14) 13 (10.5–14.5) 6 (6–8) 0.014
- FiO2 (%) 50 (40–60) 50 (40–60) 35 (26.3–43.7) 0.032
- Prone position, n (%) 10 (66.7) 10 (76.9) 0 (0) 0.036
- Recruitment manoeuvres, n (%) 5 (33.3) 5 (38.5) 0 (0) 0.509
- Length of MV (days) 10 (4–12) 11 (8–12) 3.5 (3–4) 0.074
Non-invasive ventilation, n (%) 7 (35) 5 (31.3) 2 (50) 0.587
- CPAP, n (%) 1 (14.3) 1 (20) 0 (0) 0.495
- BiPAP, n (%) 6 (85.7) 4 (80) 2 (100) 0.495
- Length of NIV (days) 2 (2–3) 2 (1.5–3.5) 2 (2–3) 0.669
Haemodynamic support
Inotropic treatment, n (%) 10 (50) 6 (37.5) 4 (100) 0.087
Inotropic due to shock, n (%) 4 (20) 0 (0) 4 (100) 0.005
Inotropic support length (days) 2 (1–4) 1.5 (1–2) 3 (2–4.7) 0.094
Maximum VIS 10 (5–26.3) 5 (5–10) 27.5 (17.5–30) 0.008
Antithrombotic prophylaxis
Heparin treatment, n (%) 19 (95) 16 (100) 3 (75) 0.200
High doses, n (%) 7 (36.8) 6 (37.5) 1 (33.3) 1.000
Specific treatment
Azithromycin, n (%) 17 (85) 14 (87.5) 3 (75) 0.509
Hydroxychloroquine, n (%) 18 (20) 16 (100) 2 (50) 0.032
Corticosteroids, n (%) 11 (55) 7 (43.8) 4 (100) 0.094
Tocilizumab, n (%) 10 (50) 9 (56.3) 1 (25) 0.582
Interferon, n (%) 5 (25) 5 (31.3) 0 (0) 0.530
Antibiotic treatment
Antibiotic requirement, n (%) 17 (85) 13 (81.3) 4 (100) 1.000
Length of antibiotic treatment (days) 7 (6.5–8.5) 7 (7–9) 6.5 (5.3–7) 0.135
Outcomes
Length of stay in paediatric ICU (days) 10 (5–16.3) 12 (5.7–17) 6 (4.3–7) 0.064
Length of stay in hospital (days) 18 (12.5–29.3) 21 (13.7–29.8) 12 (11–13) 0.170
Pulmonary thromboembolism, n (%) 1 (5) 1 (6.3) 0 (0) 1.000
Need for ECMO, n (%) 0 (0) 0 (0) 0 (0)
Mortality, n (%) 0 (0) 0 (0) 0 (0)
Values are expressed as frequency (percentage) for qualitative variables and as median (interquartile range) for quantitative variables. n: number of patients. p-value:
significant value. PRISM III Paediatric Risk of Mortality III, VIS vasoactive inotropic score, MV mechanical ventilation, NIV non-invasive ventilation, ICU Intensive Care Unit,
ECMO extracorporeal membrane oxygenation
Girona-Alarcon et al. BMC Infectious Diseases           (2021) 21:87 Page 4 of 8
1.3–7.77), and for C-reactive protein, 328.2 mg/L (IQR
252.8–351.15). The median values of the NT-proBNP
and troponins were elevated in paediatric patients.The
results of the blood tests are summarised in Table 2.
All the patients received antibiotic treatment. None of
them developed a healthcare-associated infection.
One patient developed coronary aneurisms. During
their stay in the paediatric ICU, echocardiograms
were performed routinely and showed systolic
dysfunction secondary to the shock, but no aneu-
risms were detected. The coronary aneurisms
appeared during the follow-up period, while the
patient was in the hospitalisation ward.
The paediatric patients had a median length of stay in
the ICU of 6 days (IQR 4.3–7), and they had a total
length of stay in the hospital of 12 days (IQR 11–13).
Comparison between adults and children
While adults were admitted due to ARDS, paediatric
patients required admission to the paediatric ICU due to
MIS-C (p < 0.001). Children had greater inotropic treat-
ment requirements due to the shock, while adults
needed it due to the sedation and required lower doses;
the differences in the reason for administering inotropic
treatment were statistically significant (p = 0.005).
There were differences in the blood tests. Children
had lower prothrombin time in comparison with adults
(p = 0.006). Children presented higher values of procalci-
tonin, C-reactive protein, and MR-proADM (p = 0.023,
p = 0.005, and p = 0.017, respectively).
NT-proBNP and troponins were higher in children
than in adult patients (p = 0.034 and p = 0.039,
respectively).









Mid-regional pro-adrenomedullin (nmol/L) 0.85 (0.65–1.15) 0.78 (0.64–0.88) 1.72 (1.55–2.77) 0.017
Procalcitonin (ng/mL) 0.22 (0.12–0.48) 0.19 (0.11–0.37) 5.7 (1.3–7.77) 0.023
C-reactive protein (mg/L) 181.5 (62.5–237.7) 146.95 (57.58–192.98) 328.2 (252.8–351.15) 0.005
Troponines (ng/mL) 0.004 (0.002–0.035) 0.003 (0.002–0.014) 0.09 (0.01–2.85) 0.039
NT-proBNP 2414 (59–4840) 59 (55.5–375) 4057 (2629–18,211) 0.034
Blood samples
Lymphocytes (/mm3) 1000 (700–1175) 1000 (700–1100) 1100 (475–8175) 0.703
Prothrombin time (%) 84.5 (65.6–94.8) 88 (83.3–96.8) 56.4 (47.5–63.6) 0.006
Triglycerides (mg/dL) 391 (180.5–603.5) 413 (255–623) 158 (116–167) 0.015
D-dimer, at admission (mg/L) 2.45 (1.1–5) 2.45 (0.82–4.46) 3.94 (1.35–7) 0.571
D-dimer, maximum (mg/L) 6.3 (2.1–8.6) 5.45 (1.89–9.98) 6.75 (5.63–8.33) 0.539
Ferritin, maximum (ug/L) 910 (359.7–3614.5) 999.5 (311.1–4210.5) 714.8 (567–1369.25) 0.637
Lactate dehydrogenase, maximum (IU/L) 838 (760–1464) 1053.5 (711–1616) 800 (791–819) 0.576
IL-6, maximum (pg/mL) 460.5 (52.5–1000) 709.5 (24.7–1000) 141.75 (61.1–804.75) 0.829
Microbiological data
Healthcare-associated infection, n (%) 8 (40) 8 (50) 0 (0) 0.103
CLABSI, n (%) 7 (35) 7 (43.8)
- S. epidermidis 5 (71.4) 5 (71.4)
- K. pneumoniae 1 (14.3) 1 (14.3)
- C. albicans 1 (14.3) 1 (14.3)
CAUTI, n (%) 5 (25) 5 (31.3)
- P. aeruginosa 2 (40) 2 (40)
- K. pneumoniae 1 (10) 1 (10)
- E. coli 2 (40) 2 (40)
VAP, n (%) 2 (10) 2 (40)
- R. ornithinolytica 1 (50) 1 (50)
- P. aeruginosa 1 (50) 1 (50)
Values are expressed as frequency (percentage) for qualitative variables and as median (interquartile range) for quantitative variables. n: number of
patients. p-value: significant value. IL-6 interleukin-6, CLABSI central line-associated bloodstream infection, CAUTI catheter-associated urinary tract
infection, VAP ventilator-associated pneumonia
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Discussion
The most relevant findings of this study are that chil-
dren and adults showed different manifestations related
to SARS-CoV-2: paediatric patients were admitted due
to a shock, with high inotropic requirements, and adults
presented with an ARDS, requiring mainly respiratory
support. Furthermore, biomarkers as procalcitonin and
MR-proADM could be useful to classify and stratify
these patients, since their values change depending on
the clinical manifestations.
To the best of our knowledge, this is one of the first
studies to compare the clinical and analytical differences
between critically ill adult and paediatric patients
infected with SARS-CoV-2. Moreover, since we are usu-
ally a paediatric ICU, adult patients who were sent via
referral to our unit were mainly young adults with little
or no relevant previous pathologies. This is not a com-
mon population, so we think that these results might be
interesting for other ICUs.
As far as risk factors, the adult patients in the study
had a high rate of obesity (43%). This is relevant,
because most of them had no other risk factors. It has
already been reported that obesity might be a risk factor
for respiratory diseases, as obesity is associated with a
decreased expiratory reserve volume, functional capacity,
and compliance. Moreover, the inflammatory cytokines
associated with obesity might worsen the evolution of
these patients when they contract COVID-19 infections
[14]. According to other recent articles, obesity, espe-
cially when it is related with diabetes and hypertension,
might lead to a more serious illness, requiring hospital
admission and potentially invasive ventilation [15].
The respiratory treatment of patients with ARDS
that needed MV were treated according to the
current recommendations for respiratory support [16]:
high PEEP, prone position for 16 h a day (when the
PaO2/FiO2 ratio is < 200), and recruitment manoeu-
vres (when the PaO2/FiO2 ratio is < 150, if the patient
was responsive to PEEP). This strategy was successful,
because the evolution of the patients was good over-
all, except for one partial pulmonary thromboembol-
ism. This patient was already out of the ICU when it
happened and was on a high-dose heparin treatment
regime (1 mg/kg/12 h). He needed 2 days of NIV sup-
port, without the need for inotropic agents, and his
clinical evolution was good afterwards. COVID-19 pa-
tients have several risk factors for developing pulmon-
ary thromboembolism. The most important one
seems to be the presence of an inflammatory state
that leads to hypercoagulability, but they also have
other risk factors common in critically ill patients,
like prolonged immobilisation [17]. An elevated D-
dimer value might help to identify these susceptible
patients, in order to decide on the best preventive
treatment [18, 19]. Heparin treatment is highly
recommended in all cases, at least with a prophylactic
dose, and this can then be increased depending on
the risk factors and the evolution [20]. However, in
children there are no specific recommendations, so
decisions are taken by extrapolating evidence gathered
from adult patients [21].
The respiratory support provided to children was only
due to haemodynamic reasons. This is because the clin-
ical features observed in children were completely differ-
ent. The main problem was shock, not respiratory
repercussions. They all needed high doses of inotropic
agents, which was a factor that distinguishes them from
the adult population. This is consistent with the results
of the paediatric study performed by Ramcharan et al.,
in which all patients had some degree of cardiac dys-
function and their inotropic support requirements were
high [22]. In line with this, children with MIS-C had ele-
vated NT-proBNP and troponins values in comparison
with the normal values described in paediatrics [23–25],
probably because these biomarkers are related to cardiac
dysfunction. The paediatric patients had a good evolu-
tion overall, but one of them developed coronary aneu-
rysms, which is suggestive of the Kawasaki-like disease
[26], that has been described to be related to COVID-19
in children [27].
Taking into account other parametres on the blood
test, the paediatric patients showed coagulopathy and an
increase in ferritin, lactate dehydrogenase, and D-dimer.
There are few reports about critically ill children with
COVID-19, but some of them have described similar
features, with cardiogenic shock and elevated inflamma-
tory parameters on the blood test [28].
Both paediatric and adult patients had high levels of
IL-6. This is consistent with the IL-6 signalling pathway,
which seems to be involved in the damage produced by
COVID-19. Tocilizumab, which specifically binds sol-
uble and membrane-bound IL-6 receptors, inhibits the
binding of IL-6 with its receptor, and consequently
inhibits the signal transduction; therefore, it can prevent
cytokine release syndrome in this post-infectious inflam-
matory situation [29]. We would like to remark that,
while MR-proADM and procalcitonin were normal in
adult patients, they were increased in children, probably
indicating an inflammatory situation. C-reactive protein
was elevated in all cases, but it was higher overall in
paediatric patients. The use of MR-proADM and procal-
citonin in children has been previously studied, espe-
cially for sepsis, a pathology in which both seem to be
useful [30]. Therefore, in this sample these biomarkers
might be elevated due to the multisystem inflammatory
syndrome. Concretely, MR-proADM is a pro-
inflammatory cytokine-induced peptide which has two
main effects: vasodilatation and the maintenance of the
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endothelial barrier [31]. It is a relatively new biomarker
that has been proposed as a good tool for detecting inva-
sive infections in paediatric patients [32] and also for
stratifying mortality risk in sepsis and cardiogenic shock
in adults [33–35]. We believe that its use should be
studied in larger samples, since it could be helpful to
pinpoint the risk of MIS-C patients.
In this sample, no mortality was recorded, neither in
the adults nor in the paediatric cases. In other articles,
high mortality rates have been reported (some as high as
61.5% of the patients admitted to the ICU); in most
cases, this was related to multiorgan failure and occurred
in elderly patients [36]. It is true that our population was
younger and healthier, and none of them developed mul-
tiorgan failure. However, is it not any less true that,
luckily, we were able to provide good care to the patients
in terms of the nurse-to-patient ratio, which was 1:2,
and physician-to-patient ratio, which was 1:4. Moreover,
when the pandemic arrived to Spain, we already had
Chinese reports with suggestions regarding patient man-
agement, so clearly, being prepared is crucial to improv-
ing patient outcomes. Recent works have put on the
table the important role of health workers in the man-
agement of COVID-19 pandemic and the need for an
accurate organisation for the future [37].
We acknowledge several limitations in this study. On
the one hand, the sample is relatively small, and on the
other hand, the adults are young, so the results might
not be able to be extrapolated to other populations.
However, we think that it provides valuable information,
because this is one of the first studies including both
children and young adults in critical condition.
Conclusions
To sum up, in this sample we observed two completely
different entities: adults with ARDS and children with
MIS-C. While in the first cohort the main problem was
respiratory, with ARDS and high respiratory support
requirements, in the second group the problem was
haemodynamic in nature, requiring inotropic support to
improve the situation. We believe that this could be
explained by the fact that the inflammatory response to
SARS-CoV-2 seems to be different in adult and paediat-
ric patients, being localised in the lungs or generalised in
a multisystem syndrome, respectively. However, this is a
small sample, thus further studies with larger samples
should be performed in order to confirm these findings.
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